Japan-based Kyowa Hakko Kirin Co. Ltd. established Kyowa Kirin Frontier Co. Ltd. with ¥100 million in capital.

The new company will work on getting manufacturing and marketing approval for an authorized generic of NESP, Kyowa Hakko Kirin's key product to help boost red blood cell production in kidney disease patients with anemia.

Kyowa Kirin Frontier will be headed by Wataru Murata as CEO and executive director of the board.

As of Jan. 31, US$1 was equivalent to ¥112.39.